Joseph E Carroll

US Patent:

20060099656, May 11, 2006

Filed:

Oct 3, 2005

Appl. No.:

11/242505

Inventors:

Joseph Carroll - Boulder CO, US
Aileen Healy - Medford MA, US

International Classification:

G01N 33/567

US Classification:

435007210

Abstract:

The present invention relates to methods for the diagnosis and treatment of hematological disorders. Specifically, the present invention identifies the differential expression of 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692, 58874, 252, 304, 1980, 14717, 9941, 19310, or 17832 genes in tissues relating to hematological disorders sensation, relative to their expression in normal, or non-hematological disorders disease states, and/or in response to manipulations relevant to hematological disorders. The present invention describes methods for the diagnostic evaluation and prognosis of various hematological disorders, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating hematological disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of hematological disorders.

US Patent:

20060148743, Jul 6, 2006

Filed:

Sep 1, 2005

Appl. No.:

11/217936

Inventors:

Vasant Jadhav - Longmont CO, US
Joseph Carroll - Boulder CO, US

International Classification:

A61K 48/00
C07H 21/02

US Classification:

514044000, 536023100

Abstract:

This invention relates to compounds, compositions, and methods useful for modulating histone deacetylase (HDAC) gene expression using short interfering nucleic acid (siNA) molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of HDAC genes, such as HDAC genes associated with the maintenance or development of diseases, disorders, traits, and conditions in a subject or organism such as cancer, proliferative disease, and age related disease.

US Patent:

20070185049, Aug 9, 2007

Filed:

Nov 2, 2006

Appl. No.:

11/592039

Inventors:

Vasant Jadhav - Longmont CO, US
Joseph Carroll - Boulder CO, US

Assignee:

Sirna Therapeutics, Inc. - San Francisco CA

International Classification:

A61K 48/00
C07H 21/02

US Classification:

514044000, 536023100

Abstract:

The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, disease and conditions that respond to the modulation of histone deacetylase (HDAC) gene expression and/or activity. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases and conditions that respond to the modulation of expression and/or activity of genes involved in HDAC gene expression pathways or other cellular processes that mediate the maintenance or development of such traits, diseases and conditions. Specifically, the invention relates to double stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating or that mediate RNA interference (RNAi) against HDAC gene expression, including cocktails of such small nucleic acid molecules and lipid nanoparticle (LNP) formulations of such small nucleic acid molecules. The present invention also relates to small nucleic acid molecules, such as siNA, siRNA, and others that can inhibit the function of endogenous RNA molecules, such as endogenous HDAC micro-RNA (miRNA) (e.g., miRNA inhibitors) or endogenous HDAC short interfering RNA (siRNA), (e.g., siRNA inhibitors) or that can inhibit the function of RISC (e.g., RISC inhibitors), to modulate HDAC gene expression by interfering with the regulatory function of such endogenous RNAs or proteins associated with such endogenous RNAs (e.g., RISC), including cocktails of such small nucleic acid molecules and lipid nanoparticle (LNP) formulations of such small nucleic acid molecules. Such small nucleic acid molecules are useful, for example, in providing compositions for treatment of traits, diseases and conditions that can respond to modulation of HDAC gene expression in a subject or organism, such as cancer and other proliferative diseases or conditions that are associated with HDAC gene expression or activity.